India, Sept. 30 -- Connect Biopharma Holdings Limited (CNTB) is up 24.57 percent, gaining $0.2430 to $1.2350 on Wednesday. The move comes after the company announced positive preliminary topline results from its global Phase 2 Seabreeze STAT COPD study evaluating rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation.
Connect Biopharma is currently trading at $1.2350, up from the previous close of $0.9920 after opening at $1.8850 on the Nasdaq. The stock has traded between $1.2000 and $1.8900 during the session, with trading volume at 149.92 million shares versus average volume of 1.03 million.
In the 159-participant study, rademikibart reduced treatment failure by 81 percent and new modera...